ConductScience.org, home

Trial · NCT00838903

Participant flow28

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Follow-up Period (8 Weeks)COMPLETEDPlacebo Plus Metformin75
Follow-up Period (8 Weeks)COMPLETEDSitagliptin 100 mg Plus Metformin237
Follow-up Period (8 Weeks)COMPLETEDGlimepiride 2 mg Plus Metformin243
Follow-up Period (8 Weeks)COMPLETEDAlbiglutide 30 mg Plus Metformin244
Follow-up Period (8 Weeks)NOT COMPLETEDPlacebo Plus Metformin26
Follow-up Period (8 Weeks)NOT COMPLETEDSitagliptin 100 mg Plus Metformin65
Follow-up Period (8 Weeks)NOT COMPLETEDGlimepiride 2 mg Plus Metformin64
Follow-up Period (8 Weeks)NOT COMPLETEDAlbiglutide 30 mg Plus Metformin58

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00838903/flow?page=2